Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study

PE. Romine, LM. Peterson, BF. Kurland, DW. Byrd, A. Novakova-Jiresova, M. Muzi, JM. Specht, RK. Doot, JM. Link, KA. Krohn, PE. Kinahan, DA. Mankoff, HM. Linden

. 2021 ; 23 (1) : 88. [pub] 20210823

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003906

Grantová podpora
RC1CA146456 NCI NIH HHS - United States
P01CA042045 NCI NIH HHS - United States
R50 CA211270 NCI NIH HHS - United States
P30CA047904 Medical Center, University of Pittsburgh

PURPOSE: This study evaluated the ability of 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumors. METHODS: In two separate studies, women with early stage ER+ breast cancer underwent either paired FDG-PET (n = 22) or FLT-PET (n = 27) scans prior to endocrine therapy and again in the pre-operative setting. Tissue samples for Ki-67 were taken for all patients both prior to treatment and at the time of surgery. RESULTS: FDG maximum standardized uptake value (SUVmax) declined in 19 of 22 lesions (mean 17% (range -45 to 28%)). FLT SUVmax declined in 24 of 27 lesions (mean 26% (range -77 to 7%)). The Ki-67 index declined in both studies, from pre-therapy (mean 23% (range 1 to 73%)) to surgery [mean 8% (range < 1 to 41%)]. Pre- and post-therapy PET measures showed strong rank-order agreement with Ki-67 percentages for both tracers; however, the percent change in FDG or FLT SUVmax did not demonstrate a strong correlation with Ki-67 index change or Ki-67 at time of surgery. CONCLUSIONS: A window-of-opportunity approach using PET imaging to assess early response of breast cancer therapy is feasible. FDG and FLT-PET imaging following a short course of neoadjuvant endocrine therapy demonstrated measurable changes in SUVmax in early stage ER+ positive breast cancers. The percentage change in FDG and FLT-PET uptake did not correlate with changes in Ki-67; post-therapy SUVmax for both tracers was significantly associated with post-therapy Ki-67, an established predictor of endocrine therapy response.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003906
003      
CZ-PrNML
005      
20220127145735.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13058-021-01464-1 $2 doi
035    __
$a (PubMed)34425871
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Romine, Perrin E $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 1144 Eastlake (Mail Stop LG-200), Seattle, WA, 98109-1023, USA
245    10
$a 18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study / $c PE. Romine, LM. Peterson, BF. Kurland, DW. Byrd, A. Novakova-Jiresova, M. Muzi, JM. Specht, RK. Doot, JM. Link, KA. Krohn, PE. Kinahan, DA. Mankoff, HM. Linden
520    9_
$a PURPOSE: This study evaluated the ability of 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorothymidine (FLT) imaging with positron emission tomography (PET) to measure early response to endocrine therapy from baseline to just prior to surgical resection in estrogen receptor positive (ER+) breast tumors. METHODS: In two separate studies, women with early stage ER+ breast cancer underwent either paired FDG-PET (n = 22) or FLT-PET (n = 27) scans prior to endocrine therapy and again in the pre-operative setting. Tissue samples for Ki-67 were taken for all patients both prior to treatment and at the time of surgery. RESULTS: FDG maximum standardized uptake value (SUVmax) declined in 19 of 22 lesions (mean 17% (range -45 to 28%)). FLT SUVmax declined in 24 of 27 lesions (mean 26% (range -77 to 7%)). The Ki-67 index declined in both studies, from pre-therapy (mean 23% (range 1 to 73%)) to surgery [mean 8% (range < 1 to 41%)]. Pre- and post-therapy PET measures showed strong rank-order agreement with Ki-67 percentages for both tracers; however, the percent change in FDG or FLT SUVmax did not demonstrate a strong correlation with Ki-67 index change or Ki-67 at time of surgery. CONCLUSIONS: A window-of-opportunity approach using PET imaging to assess early response of breast cancer therapy is feasible. FDG and FLT-PET imaging following a short course of neoadjuvant endocrine therapy demonstrated measurable changes in SUVmax in early stage ER+ positive breast cancers. The percentage change in FDG and FLT-PET uptake did not correlate with changes in Ki-67; post-therapy SUVmax for both tracers was significantly associated with post-therapy Ki-67, an established predictor of endocrine therapy response.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory aromatasy $x terapeutické užití $7 D047072
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádory prsu $x diagnostické zobrazování $x farmakoterapie $x metabolismus $x chirurgie $7 D001943
650    _2
$a dideoxynukleosidy $x terapeutické užití $7 D015224
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluorodeoxyglukosa F18 $x terapeutické užití $7 D019788
650    _2
$a lidé $7 D006801
650    _2
$a antigen Ki-67 $x metabolismus $7 D019394
650    _2
$a mastektomie $7 D008408
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a radiofarmaka $x terapeutické užití $7 D019275
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Peterson, Lanell M $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 1144 Eastlake (Mail Stop LG-200), Seattle, WA, 98109-1023, USA. lanell@uw.edu
700    1_
$a Kurland, Brenda F $u University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Byrd, Darrin W $u Department of Radiology, University of Washington, Seattle, WA, USA
700    1_
$a Novakova-Jiresova, Alena $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Muzi, Mark $u Department of Radiology, University of Washington, Seattle, WA, USA
700    1_
$a Specht, Jennifer M $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 1144 Eastlake (Mail Stop LG-200), Seattle, WA, 98109-1023, USA
700    1_
$a Doot, Robert K $u Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Link, Jeanne M $u Department of Diagnostic Radiology, Oregon Health and Science University, Portland, OR, USA
700    1_
$a Krohn, Kenneth A $u Department of Diagnostic Radiology, Oregon Health and Science University, Portland, OR, USA
700    1_
$a Kinahan, Paul E $u Department of Radiology, University of Washington, Seattle, WA, USA
700    1_
$a Mankoff, David A $u Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
700    1_
$a Linden, Hannah M $u Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, 1144 Eastlake (Mail Stop LG-200), Seattle, WA, 98109-1023, USA
773    0_
$w MED00006602 $t Breast cancer research : BCR $x 1465-542X $g Roč. 23, č. 1 (2021), s. 88
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34425871 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145731 $b ABA008
999    __
$a ok $b bmc $g 1751386 $s 1155055
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 1 $d 88 $e 20210823 $i 1465-542X $m Breast cancer research $n Breast Cancer Res $x MED00006602
GRA    __
$a RC1CA146456 $p NCI NIH HHS $2 United States
GRA    __
$a P01CA042045 $p NCI NIH HHS $2 United States
GRA    __
$a R50 CA211270 $p NCI NIH HHS $2 United States
GRA    __
$a P30CA047904 $p Medical Center, University of Pittsburgh
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace